| Year |
Citation |
Score |
| 2017 |
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, et al. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6. PMID 28145866 DOI: 10.7554/Elife.18970 |
0.467 |
|
| 2014 |
Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (New York, N.Y.). 346: 1480-6. PMID 25394791 DOI: 10.1126/Science.1254721 |
0.353 |
|
| 2014 |
Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proceedings of the National Academy of Sciences of the United States of America. 111: E3957-65. PMID 25201979 DOI: 10.1073/Pnas.1404221111 |
0.719 |
|
| 2014 |
Niederst MJ, Benes CH. EMT twists the road to PI3K. Cancer Discovery. 4: 149-51. PMID 24501304 DOI: 10.1158/2159-8290.CD-13-1030 |
0.344 |
|
| 2013 |
Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Science Signaling. 6: re6. PMID 24065147 DOI: 10.1126/scisignal.2004652 |
0.506 |
|
| 2013 |
O'Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. The Febs Journal. 280: 572-83. PMID 22340730 DOI: 10.1111/J.1742-4658.2012.08537.X |
0.719 |
|
| 2012 |
O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 26: 1689-92. PMID 22237780 DOI: 10.1038/Leu.2012.6 |
0.669 |
|
| 2011 |
Warfel NA, Niederst M, Newton AC. Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. The Journal of Biological Chemistry. 286: 39122-9. PMID 21908613 DOI: 10.1074/Jbc.M111.278747 |
0.735 |
|
| 2011 |
Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt Journal of Biological Chemistry. 286: 19777-19788. PMID 21454620 DOI: 10.1074/Jbc.M111.237081 |
0.677 |
|
| 2009 |
Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. The Journal of Biological Chemistry. 284: 15215-23. PMID 19324870 DOI: 10.1074/Jbc.M901468200 |
0.688 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, et al. Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6. PMID 29087937 DOI: 10.7554/Elife.33173 |
0.292 |
|
| 2024 |
Schröder M, Renatus M, Liang X, Meili F, Zoller T, Ferrand S, Gauter F, Li X, Sigoillot F, Gleim S, Stachyra TM, Thomas JR, Begue D, Khoshouei M, Lefeuvre P, ... ... Niederst M, et al. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nature Communications. 15: 275. PMID 38177131 DOI: 10.1038/s41467-023-44237-4 |
0.252 |
|
| 2016 |
Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Culazzo Pferdekamper A, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Research. PMID 26825170 DOI: 10.1158/0008-5472.Can-15-2581 |
0.233 |
|
| 2015 |
Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/Ncomms7377 |
0.224 |
|
| 2015 |
Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. The Lancet. Oncology. 16: e165-72. PMID 25846096 DOI: 10.1016/S1470-2045(14)71180-5 |
0.196 |
|
| 2015 |
Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery. 5: 713-22. PMID 25934077 DOI: 10.1158/2159-8290.CD-15-0399 |
0.195 |
|
| 2016 |
Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HC, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine. PMID 26828195 DOI: 10.1038/Nm.4040 |
0.188 |
|
| 2018 |
Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, ... ... Niederst MJ, et al. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. Jco Precision Oncology. 2018. PMID 30123863 |
0.175 |
|
| 2015 |
Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3924-33. PMID 25964297 DOI: 10.1158/1078-0432.CCR-15-0560 |
0.16 |
|
| 2016 |
Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, Sequist LV, Engelman JA. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26988570 DOI: 10.1016/j.jtho.2016.02.021 |
0.145 |
|
| 2017 |
Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, ... ... Niederst MJ, et al. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Reports. 21: 3298-3309. PMID 29241554 DOI: 10.1016/J.Celrep.2017.11.051 |
0.145 |
|
| 2017 |
Faber AC, Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, et al. Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29051323 DOI: 10.1158/1078-0432.Ccr-17-1577 |
0.1 |
|
| 2016 |
Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/J.Jtho.2016.01.012 |
0.097 |
|
| 2016 |
Niederst MJ, Engelman JA, Hata AN. Distinct evolutionary paths to TKI resistance in NSCLC. Cell Cycle (Georgetown, Tex.). 0. PMID 27552405 DOI: 10.1080/15384101.2016.1221024 |
0.07 |
|
| 2015 |
Engelman JA, Oser MG, Niederst MJ, Sequist LV. Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. The Lancet. Oncology. 16: e309-10. PMID 26149875 DOI: 10.1016/S1470-2045(15)00058-3 |
0.067 |
|
| 2015 |
Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. Jama Oncology. 1-3. PMID 26720284 DOI: 10.1001/jamaoncol.2015.5009 |
0.037 |
|
| Hide low-probability matches. |